Hippocampal‐amygdalo‐ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models. Issue 10 (7th April 2022)

• Record Type: Journal Article
• Authors: Coupé, Pierrick; Manjón, José V.; Mansencal, Boris; Tourdias, Thomas; Catheline, Gwenaëlle; Planche, Vincent
• Is Part Of: Human brain mapping. Volume 43:Issue 10(2022)
• Page Start: 3270
• Page End: 3282
• Publication Date: 2022-04-07
• Subjects: Brain mapping -- Periodicals; 611.81
• DOI: 10.1002/hbm.25850
• Languages: English
• ISSNs: 1065-9471

Abstract

Abstract: In this article, we present an innovative MRI‐based method for Alzheimer disease (AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan trajectories of brain structures. After a full screening of the most discriminant structures between AD and normal aging based on MRI volumetric analysis of 3, 032 subjects, we propose a novel Hippocampal‐Amygdalo‐Ventricular Atrophy score (HAVAs) based on normative lifespan models and AD lifespan models. During a validation on three external datasets on 1, 039 subjects, our approach showed very accurate detection (AUC ≥ 94%) of patients with AD compared to control subjects and accurate discrimination (AUC = 78%) between progressive MCI and stable MCI (during a 3‐year follow‐up). Compared to normative modeling, classical machine learning methods and recent state‐of‐the‐art deep learning methods, our method demonstrated better classification performance. Moreover, HAVAs simplicity makes it fully understandable and thus well‐suited for clinical practice or future pharmaceutical trials. Abstract : In this article, we present an innovative MRI‐based method for Alzheimer disease (AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan trajectories of brain structures. Compared to normative modeling and recent state‐of‐the‐art deep learning methods, our method demonstrated better classification performance. Moreover, it simplicity makes it fully understandable and thus well‐suited for clinical practice or future pharmaceutical trials.